LIMA1 and cancer: EPLIN was initially recognized as a novel cytoskeletal protein during a screening process, exhibiting preferential expression in human epithelial cells but often experiencing loss or downregulation in cancerous cells, where Maul and Chang first reported that the expression of EPLIN is downregulated in the majority of oral (8/8), prostate (7/7) and breast (5/6) cancer cells in 1999 [6].